Overview

The goal of this clinical trial is to learn which is better, combining Dexmedetomidine infusion and paragastric neural block or combining laparoscopic TAP block and paragastric neural block to enhance recovery after laparoscopic sleeve gastrectomy.

The main questions it aims to answer are:

Will using paragastric neural block (PGNB) combined with dexmedetomidine infusion give better recovery or using PGNB combined with laparoscopic transversus abdominis plane (LTAP) block in patients undergoing laparoscopic sleeve gastrectomy.

This will be assessed by:

Recording how much opioids were consumed by the patients Hemodynamic stability of the enrolled patients Pain scores as given by the patient The quality of postoperative patient recovery How many patients encountered nausea or vomiting

Eligibility

Inclusion Criteria:

1. American Society of Anesthesiologists (ASA) physical status II- III
2. BMI 35- 50 kg/m2

Exclusion Criteria:

1. Significant hepatic, renal, neuromuscular, or cardiac impairments
2. Extreme obesity (BMI > 50 kg/m2)
3. Patients on current opioid medication
4. Allergies to dexmedetomidine or bupivacaine